

Supplementary Information for Financial Results Q2 FY12/26

Aug 13, 2026



**To accelerate drug discovery and development of mAb
for therapeutics to overcome current medical unmet-needs**

Chiome Bioscience Inc.

- 1. Overview of Q2 FY12/26 “Financial results”**
- 2. Overview of Q2 FY12/26 “Operation highlights”**

Appendix.

Corporate information

Pipeline information

Overview of Q2 FY12/26 “Financial results”

Financial results: Profit and Loss

(JPY in millions)

	Q2 FY2025	Q2 FY2026	Increase (decrease)	Main reasons for increase / decrease
Net sales	251	273	21	
Drug Discovery & Development	-	-	-	
Drug Discovery Support	251	273	21	Decrease in research support revenue from pharmaceutical companies; increase in biosimilar-related revenue
COS/SGA	788	753	(35)	
R&D Expense	395	368	(26)	Decrease in clinical development-related costs
Other costs	392	384	(8)	
Operating Loss	(536)	(479)	57	
Ordinary Loss	(539)	(481)	57	
Net Loss	(540)	(483)	57	

Financial results: Balance Sheet

(JPY in millions)

	As of Dec. 31, 2025	As of Jun. 31, 2026
Current assets	1,546	1,733
(Cash on hand in banks)	1,205	1,372
(Other current assets)	341	361
Non-current assets	180	173
Total assets	1,727	1,907
Current Liabilities	374	285
Non-current liabilities	230	55
Total liabilities	605	341
Total net assets	1,122	1,565
Total liabilities and net assets	1,727	1,907

Financial results: Cash Flows

(JPY in millions)

	Q2 FY2025	Q2 FY2026
Cash flows from operating activities* ¹	(673)	(538)
Cash flows from investing activities	-	(3)
Cash flows from financing activities	84	709
Net increase (decrease) in cash and cash equivalents	(588)	166
Cash and cash equivalents as of the beginning of the year	2,063	1,205
Cash and cash equivalents as of the end of the period	1,474	1,372

*¹ Expenditures, such as R&D expenses mainly on clinical development, and sales, general, and administrative expenses

Overview of Q2 FY12/26 “Operation highlights”

Q2 FY12/26 Operation Highlights

Drug Discovery and Development – Pipeline

CBA-1205	✓ Patient enrollment for melanoma/hepatocellular carcinoma completed, data analysis ongoing. ✓ Dosing is ongoing in pediatric cancers part, including patients with hepatoblastoma. ✓ Received a notice of allowance for a patent on the CBA-1205/lenvatinib combination in Europe. ✓ Received a notice of allowance for a patent on the CBA-1205/FGFR4 inhibitor combination in Japan.
CBA-1535	✓ Safety and tolerability evaluation in progress for patients with solid tumors, undergoing stepwise dose escalation. ✓ The final cohort in the first part of the study started in June 2026

New technology development

DoppeLib™	✓ Collaboration with several companies underway, supported by innovative technology enabling high-throughput screening method of bispecific antibodies. Positioning this as a key technology for future IDD business to pursue new business opportunities. Introductory activities with the view of joint research with pharmaceutical companies are in progress.
------------------	---

IDD Business


Biosimilar businesses	✓ To advance the launch of new biosimilars, exploring partnerships and engaging discussions with pharmaceutical companies are ongoing. ✓ Revenue from jointly developed biosimilars recorded as drug discovery support business.
Drug Discovery Platform	✓ New project started through business alliance with Axcelead Drug Discovery Partners Inc. ✓ Advancing discussions with potential partners to generate new drug related projects, utilizing our research and drug discovery capabilities, through activities such as increased number of scientific support for Biotech startup companies before and after founding.

Drug Discovery Support Business

Deals with pharmaceutical companies	✓ Net sales of ¥273 million in 2026 2Q. Increase 8.7% in revenue ✓ Biosimilar-related revenue increased.
--	--

CBA-1205 Phase 1 Study

PR case confirmed with a hepatocellular carcinoma patient
Continued enrollment of pediatric patients incl. hepatoblastoma



First part


- Demonstrated a favorable safety profile at doses up to 30mg/kg.
- Melanoma patient maintained stable disease (SD) assessment with tumor shrinkage for more than 4 years - confirmed

Second part

- **Tumor shrinkage of more than 30% (PR)** has been observed in a **hepatocellular carcinoma patient** with confirmed expression of DLK1.
- Patient enrollment for **melanoma** and **hepatocellular carcinoma** completed, data analysis ongoing.
- Advancing **pediatric cancer** part based on joint research with IGTP in Europe and high frequency of DLK1 observed at present.


CBA-1535 Phase 1 Study

The first part of CBA-1535 Phase I study is in progress



Towards Future Out-licensing

CBA-1205: A program to maximize product value and out-licensing consideration



CBA-1535: A program aimed at out-licensing based solely on single agent data


Focusing clinical development for out-licensing with first part data, evaluation of safety and efficacy as a single agent.

⇒ Enhancing the likelihood of successful development for early-stage licensing to the companies with strong financial resources for development under this competitive T cell engager solid cancer area.

For the above clinical development programs, the aim is to acquire license agreements by obtaining data suggesting efficacy from ongoing Phase I studies.

Keep updating potential licensing partners with clinical data


Antibody Generation Technology Platforms




Basic Concept of DoppeLib™


DoppeLib™ : High throughput screening technology bispecific antibody

Conventional method



Chiome's concept






By evaluating a vast number of parental monoclonal antibody combinations, we will unlock the potential of bi-specific antibodies.

IDD Business (Biosimilars)

Leveraging CMC function and its intelligence, engaged in biosimilar business which the Japanese government actively promotes to reduce healthcare costs.

Business Scope of Chiome



Cell line development



Joint development of biosimilars

- Efficient use of management resources
- Sharing development costs
- Profit share

Clinical Development/Manufacturing and Marketing



Pursuing negotiation to increase the number of partnerships

Initiatives with Alfresa HD, Kidswell and Mycenax


Manufacturing Base

Under the MHLW's Subsidy Program for "The Development of Domestic Manufacturing Facilities for Biosimilars", Alfresa HD, Kidswell, Mycenax and Chiome are advancing the establishment of a biosimilar manufacturing facility. Joint venture Alfenax Biologics established


New biosimilars

Development of new biosimilars is in progress with Alfresa HD and Kidswell. New cell line developments are in progress, utilizing Chiome's CMC and other capabilities

Initiatives to expand biosimilar development pipeline



Business Model of Biosimilar Development





CB: Chiome Bioscience

KWB: Kidswell Bio

※1 Milestone: Income received by the licensee at each milestone after out-licensing through the progress of clinical studies and others.

※2 Royalty: Income received as a percentage of the sales amount after a product is sold (launched)

IDD Development Concept for Strengthening Consortium-based Startup Incubation




Our role: Provide bio discovery/CMC development capabilities from a manufacturing perspective

Business with pharmaceutical companies

- Net sales of ¥273 million in 2026 2Q. Increased by 8.7% year on year.
- Joint development on cell line development for biosimilars with Alfresa Holdings and Kidswell Bio is in progress and revenue related to this project increased.


(JPY in millions) Sales for Drug Discovery Support business



Major clients	Contract date
Chugai Pharmaceutical Co., Ltd.	Jun. 2011
Chugai Pharmabody Research Pte. Ltd	Aug. 2012
Tanabe Pharma Corporation	Dec. 2016
Ono Pharmaceutical Co., Ltd.	Oct. 2018
Kyowa Kirin Co., Ltd.	Jul. 2019
Takeda Pharmaceutical Co., Ltd.	Feb. 2024
Sales collaboration	Contract date
Merck Ltd. (Japan)	Sep. 2024
FUJIFILM Wako Pure Chemical Corporation	Dec. 2024

Appendix. Corporate information

Biotech company dedicating to satisfy unmet medical needs



Management principle

- Place the highest priority on sound management and credibility and aim to become a corporation that grows with society.
- With creativity and science, develop therapeutic drugs for unmet medical needs, and contribute to the health of patients.
- Achieve successive product pipelines and improvement of corporate value through collaboration with external institutions.

- Founded:
February 2005
- Listed on the stock exchange:
Dec.2011
(Tokyo Stock Exchange Growth Section)
- President and Chief Executive Officer:
Masamichi Koike, Ph.D.



- Location :
<Head Office and Research Laboratories>
3-12-1Honmachi, Shibuya-ku, Tokyo
<Drug Discovery Laboratories>
2-13-3 Nogawahonchou, Miyamae-ku,
Kawasaki-city, Kanagawa
- Number of Employees :
63 (As of Jun. 30, 2026)
- Business :
Chiome Bioscience (4583.T), is a public company leveraging a proprietary monoclonal antibody generating technology, for drug discovery and development, as well as providing drug discovery supports.

Drug Discovery and Development Business

This is business to obtain revenues such as upfront, milestone, and royalty payments relating to out-licensing of patents of pipeline product and drug candidates, and also, income from collaborative research.

It drives our future growth.

Drug Discovery Support Business

This is business to obtain revenues from antibody generation service by using platform technology that Chiome possesses to support drug discovery research at pharmaceutical companies, or for diagnostic and research purposes at academia or institutes on fee-for-service scheme.

It secures constant revenue stream.

Core Competencies that Support Our Business

Antibody drug discovery platform

Drug Discovery Research

Antibody Generation



Antibody Functional Alteration Affinity Maturation



Multivalent antibody generation



Protein preparation



Clinical development

Clinical Development PM capabilities Clinical Studies Operations



Non-clinical studies



CMC development for Biologics Manufacturing Drug Substance Manufacturing Investigational Products

Patent strategy

Antibody drug development achievement

[Drug discovery Pipeline creation & out-licensing] [IND of clinical studies/Clinical development]
[Manufacturing drug substances/investigational products]

Our advantage


Discerning eye x operational capability (from research to clinical development in the fastest/most direct way) = Chiome's drug discovery capabilities

We operate an agile research and development structure, enabling effective investment decisions with minimal resources and labor costs, while pursuing maximum returns.

Our Technologies for Next-Generation Antibodies

Multivalent Antibody Generation Technologies - the generation of lead antibodies through various combinations of targets and binding modes

[Tribody®] The technology uses Tribody®, which has three binding sites within a single molecule, making it possible to combine different functions.



[DoppeLib™: Bispecific antibody generation technology*]

Under development: Cell surface display technology for bispecific antibody generation that allows evaluating various samples in speedy manner applying ADLib® system.

*Technology that enables the flexible design of antibodies that bind to two different targets.




Antibody affinity enhancement

[ADLib® System] A method for generating human antibodies from cultured cells in vitro without using a living body (animal)

- Technology to **enhance antibody affinity** by utilizing the characteristic of autonomous gene diversification.


Pipeline Development Strategy

- Leveraging our antibody discovery platform, generate therapeutic antibodies with Academia/drug discovery venture companies to own several drug discovery pipeline projects.
- For promising seeds, promote either out-licensing to pharma companies or establishing new companies for commercialization



Revenue model


Drug development flow vs our revenue models



Contract based model	Income from contracted R&D works, consulting services and others		Offering services to research institutions, pharmaceutical companies, etc.	
		License model	Contract-based model	
	Drug Discovery Business	○		
	Drug Discovery Support Business		○	
	IDD Business	○	○	

General Image of Revenue in the Drug Discovery Business

As the stage progresses, the amount received in each milestone increases.
Royalties also to be generated at a fixed rate on sales following launch.




The above is the image of earnings to explain the Pharmaceutical Licensing Agreement. The actual agreements may vary in terms of the upfront payment, milestone stages and number/amounts of milestones, and royalty rate for each contract.

*1 Milestone: Income received by the licensee at each milestone after out-licensing through the progress of clinical studies and others.

*2 Royalty: Income received as a percentage of the sales amount after a product is sold (launched)

By integrating Human Resources, Materials, Money and Information across and beyond the company, sustainable growth is promoted by developing 3 distinct businesses through a 3-tier portfolio, enhancing corporate value



Drug Discovery Business: Research and development of drug discovery

– source of growth –

Led by CBA-1205 and CBA-1535, aiming to secure out-licensing agreements for drug discovery pipeline. Through upfront payment upon concluding agreements that will contribute to a single year PL, as well as milestones/royalty that will contribute to future revenue base, the Company aims to acquire large revenue and enhance corporate value.

Drug Discovery Support Business: R&D support, second lab services

– generating cash flow –

By offering antibody generation/antibody engineering and protein preparation, the Company aims to generate in short-term revenue through high value-added research services as a steady source of revenue

IDD: Drug Discovery platform business

– expanding business opportunities –

By leveraging technical capabilities and drug discovery expertise, the Company supports biopharmaceutical discovery for pharmaceutical companies and drug discovery startups. Its scope covers exploratory research, clinical development and biosimilar development. Contract types range from service agreements to joint R&D, with flexible frameworks to advance projects and expand business opportunities.

Service based business contributes to financial stability, while joint R&D contributes to future revenue and corporate value.

Appendix. Pipeline information

Main Pipeline

★ First in class
★★ World first drug discovery modality moving into clinical phase

Code	Target	Therapeutic Area	Status
★ CBA-1205 (ADCC enhanced)	DLK1	Oncology	Phase 1 (jRCT2080225288) (NCT06636435)
★★ CBA-1535 (Tribody®)	5T4×CD3×5T4	Oncology	Phase 1 (jRCT2031210708) (NCT07016997)
★ PCDC (ADC)	CDCP1	Oncology/ADC	Non-clinical studies in progress
PTRY (Tribody®)	5T4×CD3×PD-L1	Oncology	Non-clinical studies in progress
PXLR	CXCL1/2/3/5	Oncology	Non-clinical studies in progress
PFKR	CX3CR1	Autoimmune disease	November 2024 Out-licensed to Asahi Kasei Therapeutics Corporation (formerly Asahi Kasei Pharma Corporation)

As of Jun. 30, 2026

For other pipeline projects, we continue to work towards achieving results and report progress as appropriate.

First in class

CBA-1205 (Humanized afucosylated anti-DLK1 antibody)

Origin	A humanized antibody generated by hybridoma technology in Livtech which Chiome acquired in 2015.
ADCC	GlymaxX (ProBioGen)
Therapeutic Area	Liver cancer, lung cancer, neuroblastoma etc.
Expectation	First-in-class therapeutic antibody targeting intractable cancers. Providing new therapeutics for highly malignant tumors that are without effective therapeutic drugs including hepatocellular carcinoma.
Patent	Granted in Japan, US, Europe, China etc.

Phase I clinical study

First part: Evaluate the safety in patients with solid cancers.

- **No serious adverse reaction reported**
- **Case of a melanoma patient who maintained stable disease (SD) with tumor shrinkage for more than 4 years – confirmed**

Second part: Evaluation of safety in melanoma and hepatocellular carcinoma patients → Enrollment completed

Evaluation of safety in pediatric cancer patients → Enrollment ongoing

- **Melanoma and hepatocellular carcinoma patients is data analysis ongoing**
- **Pediatric cancer patients part is in progress**

Unmet needs to be addressed

Providing new therapeutics for highly malignant tumors with no effective treatments available, including melanoma, pediatric cancer and hepatocellular carcinoma.

CBA-1205 First Part of Phase 1 Study (Safety)

No toxicity of Grade 3 or higher were observed
High level of safety was confirmed

CBA-1205 Related Adverse Events

Adverse Events (AE)	Dose (mg /kg)							Total (n=22)
	0.1	0.3	1	3	10	20	30	
	(n=3)	(n=3)	(n=3)	(n=4)	(n=3)	(n=3)	(n=3)	
Patients with CBA-1205 Related AEs	1	0	2	3	1	3	3	13
Grade 1-2	1	0	2	3	1	3	3	13
≥ Grade 3	0	0	0	0	0	0	0	0
Dose Limiting Toxicity	0	0	0	0	0	0	0	0
Serious Adverse Events	0	0	0	0	0	0	0	0
Death	0	0	0	0	0	0	0	0
Treatment Discontinuation	0	0	0	0	0	0	0	0

(As of Jun. 30, 2026)

Only Grade 1 (mild) or Grade 2 (moderate) study drug related adverse events were reported at each dose. No Grade 3 (severe or medically significant but not immediately life-threatening) or higher serious toxicity findings were reported. No adverse reactions that would have stopped dosing were reported, and the high safety of CBA-1205 was confirmed.


CBA-1535 (Humanized anti 5T4 & CD3 trispecific antibody)

Origin	CBA-1535 is a T-cell engager, trispecific antibody, directed against the 5T4 tumor antigen, a protein found on various solid tumors and is thought to be involved in metastasis.
Therapeutic Area	Malignant mesothelioma, small cell lung cancer, non small cell lung cancer, TNBC etc.
Expectation	First-in-class therapeutic antibody with trispecific format Offer a new treatment option for a disease which has poor prognosis and where there are only a few effective treatments.
Patent	Granted in Japan, UK, US, EU China etc.

Phase I study: Dosing for patients has started in the first part for safety and initial drug efficacy evaluation.

Study sites: National Cancer Center Hospital

Shizuoka Cancer Center



Unmet needs to be addressed

Providing new therapeutics for solid tumors with poor prognosis and limited effective treatment options, including malignant mesothelioma.

PCDC (humanized anti-CDCP1 antibody for antibody drug conjugate)


Origin	Humanized anti-CDCP1 antibody discovered by Chiome's proprietary antibody technologies.
Therapeutic Area	Solid tumors (lung, colorectal, pancreatic, breast, ovarian etc.)
Expectation	CDCP1 is a First-in-class therapeutic target highly expressed in broad range of solid tumors, including standard-of-care resistant cases. High efficacy and safety expected from binding and toxicological profiles of the antibody.
Patent	Granted in Japan, China etc. Pending in US, Europe etc.

- Promoting out-licensing activities, mainly in the field of ADC
- Progressing in contacting out-licensing candidate companies in Japan and abroad at conferences.

Out-licensing strategy/target

As the development needs for combining the ADC technology and our antibodies are in higher demand in out-licensing candidate companies, we will prioritize our out-licensing activities with companies with ADC technologies who need antibodies for ADC.


Antibody-Drug Conjugate Technology



PTRY (humanized antibody 5T4/CD3/PD-L1 multi-specific antibodies)

Target molecules : 5T4×CD3×PD-L1

Origin	Therapeutic antibodies for cancer treatment using Tribody® technology consisting of three binding sites. Therapeutic antibodies for cancer treatment targeting antigen-binding sites 1) solid tumor expressing 5T4, 2) T-cell engager CD3, and 3) immune checkpoint inhibitor PD-L1.
Therapeutic Area	Malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, Triple Negative Breast Cancer (TNBC) etc.
Expectation	A new study drug for patients who have not responded adequately to standard cancer immunotherapy. It is also expected to be useful in contributing to the healthcare economy by reducing drug prices.
Patent	Patent application completed



The results of the joint research with Ceinge Biotechnologie Avanzate (“Ceinge”) in Italy were published in the Journal of Experimental & Clinical Cancer Research, and Cancers.

[Passariello et al. \(2022\). Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo. *Journal of experimental & clinical cancer research* : CR, 41\(1\), 269.](#)


[Manna et al. \(2023\). A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies. *Cancers*, 15\(22\), 5345](#)

PXLR -Licensing-


PXLR (humanized anti-CXCL1/2/3/5 antibody) Target molecules: CXCL1/2/3/5

Origin	Functional inhibitory antibody for CXCL1/2/3/5, chemoattractant of CXCR2 expressing cell. Cancer therapeutic antibody that improves drug-resistant cancer microenvironment
Therapeutic area	Solid tumors (gastric, breast, ovarian etc.)
Expectation	Cancer cells express CXCL1/2/3/5 and attract immunosuppressor cells that cause the drug-resistant environment. Dosing PXLR antibody will reduce immunosuppressor cells. It is expected to overcome drug-resistance and inhibit the recurrence of cancers.
Patent	Patent application completed.
Joint development partner(s)	Osaka Metropolitan University

Drug resistant environment



Weakening of drug-resistant environment




CXCL1/2/3/5 is a ligand of CXCR2, G-protein-coupled receptor (GPCR), and is involved in various tumorigenesis and formation processes. Cancer cells attract immunosuppressive cells with CXCL1/2/3/5 and create a drug-resistant environment. PXLR weakens drug resistant ability of cancer cells by binding to CXCL1/2/3/5.

PFKR -Out-Licensed Products-

PFKR (humanized anti-CX3CR1 antibody) target molecules: CX3CR1

Origin	Functional inhibitory antibody of Fractalkine (CX3CL1) receptor and a therapeutic antibody that inhibits disease progression of autoimmune neurological diseases, etc.
Therapeutic area	Secondary Progressive Multiple Sclerosis (SPMS), neurodegenerative disorder etc.
Expectation	SPMS is an intractable form of multiple sclerosis and is a disease with a need to develop high safety and effective therapeutic agents. By suppressing cytotoxic Eomes-positive CD4+T cells function which are considered directly related to lesions in SPMS (demyelination, neurodegeneration), expected to inhibit the progression of symptoms.
Patent	Patent application completed
Joint development partner(s)	National Center of Neurology and Psychiatry



CX3CR1 is a type of G protein-coupled receptor(GPCR), and its ligand, Fractalkine (CX3CL1), causes the migration of CX3CR1-expressing cells to inflammatory sites.

In cytotoxic Eomes positive CD4+T cells, which are considered directly related to lesions in SPMS (demyelination, neurodegeneration), CX3CR1 is expressed in many.

PFKR: Exclusive License Agreement with Asahi Kasei Therapeutics Corporation

- Exclusive license agreement with Asahi Kasei Therapeutics Corporation (formerly Asahi Kasei Pharma Corporation) for our therapeutic antibody, —humanized anti-CX3CR1 antibody (project code: PFKR)—, on November 20, 2024
- Under the terms of the agreement, we grant Asahi Kasei Pharma worldwide license, with the right to grant sublicenses for the development, manufacturing and commercialization of PFKR



Financial terms

- ◆ Upfront payment: ¥200 million
- ◆ Receive milestone payments based on future development and sales progress (up to ¥24.8 billion)



- ◆ After product launch
Royalties based on product net sales

Shine light on unmet needs. Bring a brighter future to patients.

To accelerate drug discovery and development of mAb
for therapeutics to overcome current medical unmet-needs



- Materials and information provided during this presentation may contain so-called “forward-looking statements.” These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations.
- The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.